Saol Therapeutics Completes Enrollment in Pivotal Phase III BEACON Trial for SL1002 in Chronic Pain Management

Saol Therapeutics Completes Enrollment in BEACON Trial

Saol Therapeutics, a clinical-stage pharmaceutical company focused on innovative therapies, has announced a significant development in its ongoing research. On October 2, 2026, the company confirmed that they have completed patient enrollment for the BEACON Trial, a pivotal Phase III clinical study evaluating its investigational product, SL1002. This trial aims to assess SL1002's efficacy in treating chronic pain stemming from osteoarthritis of the knee, a condition affecting millions worldwide.

A Landmark Achievement

The BEACON Trial (NCT07226258) is designed as a randomized, double-blind, placebo-controlled study and involves over 20 sites across the United States. This robust design is aimed at ensuring that the results will effectively demonstrate the safety and efficacy of SL1002 in managing chronic knee pain, providing a much-needed alternative to existing treatment options that are often inadequate or come with significant side effects.

Dave Penake, the CEO of Saol Therapeutics, expressed optimism regarding this critical milestone, stating, "Completing enrollment in BEACON is another significant step forward for the SL1002 program and most importantly, for the patients living with chronic knee pain that currently have limited non-opioid treatment options."

The Need for Effective Treatments

Chronic knee pain due to osteoarthritis presents a considerable challenge for patients and healthcare providers alike. Many individuals struggle with limited choices that can lead to dependency on opioids or inadequate pain relief. Moreover, osteoarthritis is prevalent in the aging population, making the need for innovative therapies even more pressing.

Dr. Ameet Nagpal, the Principal Investigator from the Medical University of South Carolina, echoed this sentiment, emphasizing the importance of SL1002 in expanding therapeutic options for patients with chronic knee pain. He stated, "There are millions of patients who are dealing with chronic knee pain related to osteoarthritis, and our team at MUSC is proud to have been part of another study with Saol Therapeutics to try to bring these patients a new non-opioid treatment option."

Future Directions

In addition to the BEACON Trial, Saol Therapeutics is preparing for an End-of-Phase II meeting with the FDA to discuss the clinical development program of SL1002 for spasticity, another potential application of this investigational drug. This expansion of research underlines Saol's commitment to exploring the comprehensive potential of SL1002 beyond just chronic pain management in osteoarthritis.

"Our upcoming End-of-Phase II meeting reflects the breadth of opportunity we see for SL1002 beyond a single indication," Penake added, highlighting the company's ambition to address several conditions that affect many in the U.S.

About SL1002 and Saol Therapeutics

SL1002 is categorized as a targeted perineural chemoneurolytic injection that utilizes Saol's proprietary CYCLOPHLEX™ technology. While it is still under investigation and has not yet received FDA approval, its potential applications span various conditions linked to chronic pain and spasticity.

Saol Therapeutics operates from key locations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda, focusing on advancing therapeutic options for Central Nervous System (CNS) disorders and orphan diseases. The company remains dedicated to improving patient outcomes through innovative solutions, underlining its commitment to research and development in the healthcare sector.

In conclusion, the completion of enrollment in the BEACON Trial marks a pivotal moment for Saol Therapeutics, signaling progress in addressing chronic knee pain through the innovative SL1002. As the company anticipates positive topline results in the second quarter of 2027, interest grows around the broader implications of this treatment advancement in managing debilitating conditions. With ongoing efforts in the pipeline, Saol is poised to contribute significantly to the field of pain management.